No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.0x · 10Y median 1.0x · 75th percentile · as of Oct 6, 2026
Annual revenue · last 3 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:22:32.447Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T22:22:32.447Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T22:22:32.447Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T22:22:32.447Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T22:22:32.447Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T22:22:32.447Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T22:22:32.447Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Lumexa Imaging Holdings, Inc. Common Stock (LMRI) stock was $10.71 as of Oct 6, 2026, 4:00 PM EDT, down 0.56% from the previous close.
Lumexa Imaging Holdings, Inc. manages and operates diagnostic imaging centers throughout the United States.
Medical - Devices · Raleigh, NC
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
0.20
Revenue Est.
$270.27M
Last Quarter Results
EPS
$0.20
vs Estimate
$0.15
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LMRI | $1.03B | $10.71 | -0.56% | N/A | N/A | N/A | N/A |
| 2JANX | $1.02B | $16.79 | +1.51% | -30.96% | -6.45% | N/A | vs LMRI |
| 3IART | $1.04B | $13.32 | +0.23% | -10.16% | -28.16% | -10.66% | vs LMRI |
| 4CSTL | $1.02B | $33.36 | -8.98% | +60.94% | -10.28% | N/A | vs LMRI |
| 5TDOC | $1.05B | $5.77 | -0.35% | -35.60% | -45.85% | -10.53% | vs LMRI |
| 6IMTX | $1.01B | $7.50 | -2.98% | -17.69% | -9.88% | N/A | vs LMRI |
forward FY estimate
16.68
$264.16M
vs Estimate
$263.12M
Consensus Rating
Based on 9 analysts
Average Price Target
$17.67
+65.0% upside
Low
$13.00
Current
$10.71
High
$23.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.14 | $0.16 | $0.17 | 5 |
| Quarter ending Dec 2026 | $0.17 | $0.19 | $0.21 | 5 |
| Quarter ending Mar 2027 | $0.17 | $0.18 | $0.18 | 3 |
| Quarter ending Jun 2027 | $0.19 | $0.20 | $0.21 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.61 | $0.64 | $0.70 | 5 |
| FY 2027 | $0.81 | $0.83 | $0.86 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $266.09M | $270.27M | $272.78M | 6 |
| Quarter ending Dec 2026 | $273.24M | $280.56M | $287.60M | 6 |
| Quarter ending Mar 2027 | $259.26M | $266.03M | $272.89M | 3 |
| Quarter ending Jun 2027 | $270.76M | $277.83M | $284.99M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.05B | $1.07B | $1.08B | 7 |
| FY 2027 | $1.10B | $1.12B | $1.13B | 7 |
